Cargando…

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

PURPOSE: The aim of this study was to evaluate the risk of immune-related adverse events (irAEs) among cancer patients receiving nivolumab-plus-ipilimumab therapy and nivolumab monotherapy. PATIENTS AND METHODS: PubMed and Web of Science were searched for related studies from inception to June 2018....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shi, Khanal, Samrat, Zhang, Haijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362938/
https://www.ncbi.nlm.nih.gov/pubmed/30774357
http://dx.doi.org/10.2147/TCRM.S193338
_version_ 1783393025164050432
author Zhou, Shi
Khanal, Samrat
Zhang, Haijun
author_facet Zhou, Shi
Khanal, Samrat
Zhang, Haijun
author_sort Zhou, Shi
collection PubMed
description PURPOSE: The aim of this study was to evaluate the risk of immune-related adverse events (irAEs) among cancer patients receiving nivolumab-plus-ipilimumab therapy and nivolumab monotherapy. PATIENTS AND METHODS: PubMed and Web of Science were searched for related studies from inception to June 2018. Eligible studies included randomized controlled trials comparing nivolumab-plus-ipilimumab with nivolumab alone in cancer patients reporting on all-grade (grade 1–4) and high-grade (grade 3/4) irAEs. Paired reviewers selected studies for inclusion and extracted data. The odds risk and 95% CI were calculated. RESULTS: A total of 2,946 patients from four studies were included in the meta-analysis. The underlying malignancies included lung cancer (two trials) and melanoma (two trials). Compared with nivolumab monotherapy, the nivolumab-plus-ipilimumab therapy was associated with a significantly higher risk of all- and high-grade irAEs such as pruritus, rash, diarrhea, colitis, alanine aminotransferase elevation, and pneumonitis. CONCLUSION: The combination therapy of nivolumab and ipilimumab increased the incidence of irAEs in patients with advanced cancer.
format Online
Article
Text
id pubmed-6362938
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63629382019-02-15 Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients Zhou, Shi Khanal, Samrat Zhang, Haijun Ther Clin Risk Manag Review PURPOSE: The aim of this study was to evaluate the risk of immune-related adverse events (irAEs) among cancer patients receiving nivolumab-plus-ipilimumab therapy and nivolumab monotherapy. PATIENTS AND METHODS: PubMed and Web of Science were searched for related studies from inception to June 2018. Eligible studies included randomized controlled trials comparing nivolumab-plus-ipilimumab with nivolumab alone in cancer patients reporting on all-grade (grade 1–4) and high-grade (grade 3/4) irAEs. Paired reviewers selected studies for inclusion and extracted data. The odds risk and 95% CI were calculated. RESULTS: A total of 2,946 patients from four studies were included in the meta-analysis. The underlying malignancies included lung cancer (two trials) and melanoma (two trials). Compared with nivolumab monotherapy, the nivolumab-plus-ipilimumab therapy was associated with a significantly higher risk of all- and high-grade irAEs such as pruritus, rash, diarrhea, colitis, alanine aminotransferase elevation, and pneumonitis. CONCLUSION: The combination therapy of nivolumab and ipilimumab increased the incidence of irAEs in patients with advanced cancer. Dove Medical Press 2019-01-31 /pmc/articles/PMC6362938/ /pubmed/30774357 http://dx.doi.org/10.2147/TCRM.S193338 Text en © 2019 Zhou et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Zhou, Shi
Khanal, Samrat
Zhang, Haijun
Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
title Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
title_full Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
title_fullStr Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
title_full_unstemmed Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
title_short Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
title_sort risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362938/
https://www.ncbi.nlm.nih.gov/pubmed/30774357
http://dx.doi.org/10.2147/TCRM.S193338
work_keys_str_mv AT zhoushi riskofimmunerelatedadverseeventsassociatedwithipilimumabplusnivolumabandnivolumabtherapyincancerpatients
AT khanalsamrat riskofimmunerelatedadverseeventsassociatedwithipilimumabplusnivolumabandnivolumabtherapyincancerpatients
AT zhanghaijun riskofimmunerelatedadverseeventsassociatedwithipilimumabplusnivolumabandnivolumabtherapyincancerpatients